Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
R Singh, A Letai, K Sarosiek - Nature reviews Molecular cell biology, 2019 - nature.com
The loss of vital cells within healthy tissues contributes to the development, progression and
treatment outcomes of many human disorders, including neurological and infectious …
treatment outcomes of many human disorders, including neurological and infectious …
Why do BCL-2 inhibitors work and where should we use them in the clinic?
Intrinsic apoptosis is controlled by the BCL-2 family of proteins but the complexity of intra-
family interactions makes it challenging to predict cell fate via standard molecular biology …
family interactions makes it challenging to predict cell fate via standard molecular biology …
Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy
CN Harrison, JS Garcia, TCP Somervaille… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Targeting the BCL-XL pathway has demonstrated the ability to overcome Janus
kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy …
kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy …
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition
Since its discovery, the Janus kinase-signal transduction and activation of transcription (JAK-
STAT) pathway has become recognized as a central mediator of widespread and varied …
STAT) pathway has become recognized as a central mediator of widespread and varied …
Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy
Protein kinases have grown over the past few years as a crucial target for different cancer
types. With the multifactorial nature of cancer, and the fast development of drug resistance …
types. With the multifactorial nature of cancer, and the fast development of drug resistance …
Cancer stem cell metabolism: a potential target for cancer therapy
Abstract Cancer Stem cells (CSCs) are a unipotent cell population present within the tumour
cell mass. CSCs are known to be highly chemo-resistant, and in recent years, they have …
cell mass. CSCs are known to be highly chemo-resistant, and in recent years, they have …
Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
ABT-199, a potent and selective small-molecule antagonist of BCL-2, is being clinically
vetted as pharmacotherapy for the treatment of acute myeloid leukemia (AML). However …
vetted as pharmacotherapy for the treatment of acute myeloid leukemia (AML). However …
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
P Ramesh, JP Medema - Apoptosis, 2020 - Springer
Apoptosis is a form of programmed cell death that is essential for tissue homeostasis. De-
regulation of the balance between proliferation and apoptosis contributes to tumor initiation …
regulation of the balance between proliferation and apoptosis contributes to tumor initiation …
Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer
C Li, G Zhang, L Zhao, Z Ma, H Chen - World journal of surgical oncology, 2015 - Springer
Nearly a century ago, Otto Warburg made the ground-breaking observation that cancer cells,
unlike normal cells, prefer a seemingly inefficient mechanism of glucose metabolism …
unlike normal cells, prefer a seemingly inefficient mechanism of glucose metabolism …
Biology and therapeutic targeting of molecular mechanisms in MPNs
J How, JS Garcia, A Mullally - Blood, 2023 - ashpublications.org
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders
characterized by activated Janus kinase (JAK)–signal transducer and activator of …
characterized by activated Janus kinase (JAK)–signal transducer and activator of …